Opdivo (nivolumab) in Combination with Cisplatin-Based Chemotherapy Followed by Opdivo Demonstrates Significant Survival Benefits for Cisplatin-Eligible Patients with Unresectable or Metastatic Urothelial Carcinoma in Phase 3 CheckMate -901 Trial
Opdivo in combination with cisplatin-based chemotherapy followed by Opdivo monotherapy reduced the risk of death by 22% for patients with…